CLVS vs. RGLS, CBIO, INFI, MTEM, ADIL, LMNL, DFFN, LABP, PULM, and APGN
Should you be buying Clovis Oncology stock or one of its competitors? The main competitors of Clovis Oncology include Regulus Therapeutics (RGLS), Catalyst Biosciences (CBIO), Infinity Pharmaceuticals (INFI), Molecular Templates (MTEM), Adial Pharmaceuticals (ADIL), Liminal BioSciences (LMNL), Diffusion Pharmaceuticals (DFFN), Landos Biopharma (LABP), Pulmatrix (PULM), and Apexigen (APGN). These companies are all part of the "pharmaceutical preparations" industry.
Clovis Oncology vs.
Regulus Therapeutics (NASDAQ:RGLS) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.
Regulus Therapeutics has a net margin of 0.00% compared to Clovis Oncology's net margin of -189.37%. Clovis Oncology's return on equity of 0.00% beat Regulus Therapeutics' return on equity.
In the previous week, Regulus Therapeutics had 6 more articles in the media than Clovis Oncology. MarketBeat recorded 7 mentions for Regulus Therapeutics and 1 mentions for Clovis Oncology. Regulus Therapeutics' average media sentiment score of 1.02 beat Clovis Oncology's score of 0.00 indicating that Regulus Therapeutics is being referred to more favorably in the media.
Regulus Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Clovis Oncology received 109 more outperform votes than Regulus Therapeutics when rated by MarketBeat users. However, 67.91% of users gave Regulus Therapeutics an outperform vote while only 65.58% of users gave Clovis Oncology an outperform vote.
Regulus Therapeutics currently has a consensus price target of $9.00, suggesting a potential upside of 971.43%. Given Regulus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regulus Therapeutics is more favorable than Clovis Oncology.
55.5% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 24.5% of Clovis Oncology shares are held by institutional investors. 8.3% of Regulus Therapeutics shares are held by company insiders. Comparatively, 4.4% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Regulus Therapeutics has higher earnings, but lower revenue than Clovis Oncology. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Regulus Therapeutics beats Clovis Oncology on 13 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Clovis Oncology Competitors List
